2012 Annual Report A Change for the Better  Lucja Blesi For the past six years, Lucja Blesi, a 42-year-old  mother of two and book dealer in St. Gallen, Swit - zerland, has been battling rheumatoid arthritis. It started as a mysterious joint swelling of a finger,  and then worsened until her hands, feet and other  joints were affected. The pain was constant and  impaired her ability to walk. “I was unable to get up  in the morning,” Blesi recalls. And while a standard  therapy subsequently relieved much of the pain, “It  was difficult to go on vacation. Many acute flareups  still caused severe bouts of pain,” she admits. In 2011, her rheumatologist, Rüdiger Müller, M.D., at the Cantonal Hospital of St. Gallen, prescribed  Orencia  IV. Her acute episodes have decreased and  now she is back to taking walks and even skiing.  Recently, Müller switched her to the newly approved  subcutaneous formulation of  Orencia  so that she can  administer the medication herself. He is enthusiastic  about the broadened options for using  Orencia . “This  way,” he says, “we can treat patients with  Orencia according to their preferred mode of administration.” “When I used to have these terrible episodes,” Blesi  says, “I would think, ‘Why me? Why now?’ But now  I am getting back to doing the things I used to do.” care and encourage best practices. initiative to improve the quality of life  for women living with HIV. The program  seeks to educate health care provid- ers about the special needs of women  while also empowering women to get  the most out of health care services.  SHE “units,” multidisciplinary teams  based in clinics and hospitals, have  been established at 16 health facilities  in Europe, with 32 more planned for  2013. The teams draw on SHE pro- gram medical and peer support mate- rials and faculty expertise to improve  Baraclude  sales were $1.4 billion in  2012, with over 80 percent of sales  coming from outside the U.S., including  35 percent growth in China, its largest  market. About three-quarters of the  350 million people worldwide infected  with hepatitis B virus are in Asia,  including more than 90 million in China.  The growth of  Baraclude  as first-line  therapy for chronic hepatitis B infection  is supported by data demonstrating  sustained viral load reduction, minimal  resistance and a favorable long-term  safety profile, along with disease  awareness efforts about understanding  how the disease affects the liver. r Looking to the future, studies are  underway of a novel interferon, pegin- terferon lambda-1a, both as a poten- tial stand-alone hepatitis B treatment  and as part of combination treatment  with  Baraclude . Baraclude Bristol-Myers Squibb  7